logo
Share SHARE
FONT-SIZE Plus   Neg

Shire's DERMAGRAFT Approved In Canada For Treating Diabetic Foot Ulcers

Shire Plc (SHP.L, SHPG) said its lead regenerative medicine product, DERMAGRAFT (human fibroblast-derived dermal substitute) secured regulatory approval from Health Canada as a class IV medical device for the treatment of diabetic foot ulcers (DFUs), a complication of diabetes.

Shire Regenerative Medicine plans to make DERMAGRAFT available in Canada in the first quarter of 2013, and will leverage Shire's current infrastructure and commercial knowledge of the Canadian healthcare system.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A Brazilian judge has ordered all wireless phone carriers in the country to block WhatsApp after the Facebook-owned messaging service failed to comply with an order asking to turn over data related to a criminal investigation. According to reports, the app, which is used by over 100 million Brazilians,... Amazon.com Inc. intends to bring its free same-day delivery to the Bronx and Chicago's South Side areas. The online retailer's plans comes after severe criticism were raised that the company unfairly left out some predominantly black and Hispanic areas from its Prime service. An analysis done by... Sprint Corp., the third largest U.S. wireless carrier, on Tuesday reported a loss for the fourth quarter that widened from last year on one-time charges and lower revenues. The latest quarter's results include charges related to severance and lease exit costs, including the shutdown of legacy WiMAX service that will free up valuable spectrum and immediately lower network costs.
comments powered by Disqus
Follow RTT